BeiGene | The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

Beigene Study ID

BGB-A317/BGB-290_Study_001

ClinicalTrials.gov ID

NCT02660034

EudraCT Number

2017-003580-35

Sex: All

Age: 18 Years / N/A

Study Protocol Statistical Analysis Plan

Sex: All

Age: 18 Years / N/A

Study Protocol Statistical Analysis Plan